Cost-effectiveness analysis of irinotecan+5FU/FA as first-line therapy in advanced colorectal cancer.

被引：0
|
作者：
Schmitt, C
Levy-Piedbois, C
Frappé, M
Durand-Zaleski, I
Gruia, G
Alakl, M
Rougier, P
机构：
[1] Hop Ambroise Pare, Boulogne, France
[2] Aventis Pharma, Antony, France
[3] Hop Henri Mondor, Dept Publ Hlth, F-94010 Creteil, France
[4] Inst Gustave Roussy, Dept Publ Hlth & Informat, Villejuif, France
[5] Phoenix Int, MDS Pharma Serv, Sevres, France
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
202P
引用
收藏
页码：47 / 47
页数：1
相关论文
共 50 条
  • [1] Phase II study of irinotecan+5FU/FA for patients with previously treated advanced gastric cancer.
    Peeters, M
    Van Laethem, JL
    Baert, F
    Canon, JL
    De Grève, J
    Kalantari, H
    Dhont, P
    Van Cutsem, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 332S - 332S
  • [2] Cost-effectiveness of oxaliplatin/5FU/LV (FOLFOX) vs. irinotecan/5FU/LV (IFL) as first-line treatment of metastatic colorectal cancer
    Aballea, S.
    Najib, M.
    Cure, S.
    O'Neil, B.
    ANNALS OF ONCOLOGY, 2006, 17 : 66 - 66
  • [3] Cost-effectiveness of irinotecan in advanced colorectal cancer
    Trippoli, S
    Vaiani, M
    Cattel, F
    Messori, A
    ANNALS OF ONCOLOGY, 2000, 11 (07) : 899 - 900
  • [4] Combination with irinotecan - the reference first-line therapy for advanced colorectal cancer
    Wilke, HW
    ONKOLOGIE, 2000, 23 : 32 - 34
  • [5] Cost-effectiveness analysis of irinotecan compared with best estimated infusional 5-FU regimen in patients with advanced colorectal cancer
    Neymark, N
    Adriaenssen, I
    Schmitt, C
    MEDICAL DECISION MAKING, 1998, 18 (04) : 461 - 461
  • [6] Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 194 - 198
  • [7] CONSEQUENCES OF BIOMARKER ANALYSIS ON THE COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH IRINOTECAN BASED CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER. STRATIFIED MEDICINE AT WORK?
    Harty, G. T.
    Jarrett, J.
    Jofre-Bonet, M.
    VALUE IN HEALTH, 2015, 18 (07) : A456 - A456
  • [8] Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer
    Ruiz-Millo, Oreto
    Albert-Mari, Asuncion
    Sendra-Garcia, Ana
    Victor Jimenez-Torres, N.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2014, 20 (05) : 341 - 350
  • [9] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
    Wu, Meiyu
    Qin, Shuxia
    Wang, Liting
    Tan, Chongqing
    Peng, Ye
    Zeng, Xiaohui
    Luo, Xia
    Yi, Lidan
    Wan, Xiaomin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [10] Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials
    Folprecht, G.
    Seymour, M. T.
    Saltz, L.
    Douillard, J. Y.
    Stephens, R. J.
    Van Cutsem, E.
    Rougier, P.
    Maughan, T. S.
    Koehne, C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345